ABSTRACT
This review is devoted to the management of primary artery thrombosis (PAT). This disease was always considered only as a part of other venous thromboembolic events, in particular isolated pulmonary embolism (PE). Various studies show that PAT can develop as an independent event without concomitant damage to extra-vessels. PAT is characterized by own typical signs as primary and recurrent event that can determine special strategies of treatment. However, there are no studies devoted to this problem. We can only make some assumptions about PAT anticoagulation (AC) considering data on isolated PE comprising PAT. These data are available in PADIS-PE, ASPIRE, EINSTEIN-PE, Hokusai-VTE studies underlying modern guidelines of various societies. In the absence of studies on PAT AC these guidelines should regulate PAT AC approaches. AC is recommended in all cases of PE except isolated subsegmental PAT in ambulatory patients. Duration of AC depends on risk factors (major or minor). Anticoagulation for PAT following chronic inflammatory diseases is still disputable.
Subject(s)
Pulmonary Embolism , Thrombosis , Venous Thromboembolism , Venous Thrombosis , Anticoagulants , Humans , Pulmonary Artery , Pulmonary Embolism/diagnosis , Pulmonary Embolism/drug therapy , Thrombosis/diagnosis , Thrombosis/drug therapy , Thrombosis/etiologyABSTRACT
Widely incorporated into vascular surgery pharmacological thrombolysis in treatment for deep vain thrombosis is fraught with a series of unsolved problems requiring further consideration. In spite of aggressive nature of treatment in a series of cases pharmacological thrombolysis sometimes turns out ineffective. Along with it, the results of experimental studies suggest a possibility of accelerating resorption of thrombotic masses and inhibiting remodelling of the venous wall by means of influencing effector cells of endogenous thrombolysis. A detailed study of the mechanisms of thrombolysis would make it possible to formulate strict criteria for carrying out pharmacological thrombolysis and to increase its efficacy.
Subject(s)
Antithrombins , Catheterization, Peripheral/methods , Fibrinolysis , Thrombolytic Therapy/methods , Venous Thrombosis , Antithrombins/metabolism , Antithrombins/pharmacology , Combined Modality Therapy , Fibrin/metabolism , Humans , Outcome Assessment, Health Care , Venous Thrombosis/drug therapy , Venous Thrombosis/metabolism , Venous Thrombosis/surgeryABSTRACT
The fifth Hands-on Workshop on Venous Diseases of the European Venous Forum was held from October 30 to November 1, 2014 in Limassol, Cyprus. Leading specialists from European countries for three days delivered reports concerning modern trends in diagnosis and treatment of venous diseases. The participants of the hands-on workshop had a unique possibility to learn first-hand the latest recommendations concerning diagnosis and treatment of varicose disease, acute venous thromboses, post-thrombotic disease, to know about advanced technologies being just introduced into clinical practice.
